Datopotamab Deruxtecan Approved, Immunotherapy Timing, and Rising Early-Onset Colorectal Cancer
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Unfollow podcast failed
Datopotamab Deruxtecan Approved, Immunotherapy Timing, and Rising Early-Onset Colorectal Cancer
-
Narrated by:
-
By:
In this episode of Curie, Matt covers three major developments in oncology. The FDA has approved datopotamab deruxtecan (Datroway) for HR positive, HER2 negative breast cancer, marking a new era for antibody-drug conjugates in this disease. A meta-analysis suggests that the timing of immunotherapy infusions may impact survival outcomes, raising questions about how circadian rhythms influence treatment response. Finally, a global analysis confirms that early-onset colorectal cancer is on the rise worldwide, challenging current screening guidelines and prompting discussions on prevention strategies. Tune in for the latest insights shaping cancer care.
adbl_web_anon_alc_button_suppression_t1
No reviews yet